Global News

Teva completes acquisition of Auspex Pharmaceuticals

Wednesday, May 6, 2015 02:39 PM

Teva Pharmaceutical Industries has completed the acquisition of Auspex Pharmaceuticals through the successful tender offer for all of the outstanding shares of common stock of Auspex at $101 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. The acquisition is expected to enhance Teva’s revenue and earnings growth profile and strengthen its core central nervous system franchise. Auspex now is a wholly owned subsidiary of Teva.

More... »

Quest Diagnostics

CytRx’s Aldoxorubicin shows improved QoL in chemotherapy resistant cancers

Monday, May 4, 2015 02:33 PM

CytRx, a biopharmaceutical R&D company specializing in oncology, has announced an interim analysis from its two ongoing phase Ib aldoxorubicin combination studies pairing aldoxorubicin with either gemcitabine or ifosfamide. Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well-tolerated, and even at the lowest dose level of aldoxorubicin (170mg/m2), impressive tumor responses have been observed so far in patients with bone cancer (osteosarcoma) and a variety of soft tissue sarcomas. As such, aldoxorubicin has the potential when used in combination with other cancer agents to become an important new weapon against chemotherapy resistant cancers.

More... »


Can-Fite subsidiary OphthaliX to acquire Improved Vision Systems

Monday, May 4, 2015 01:25 PM

Can-Fite BioPharma, an Israeli biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, has announced its subsidiary, OphthaliX, has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems (IVS).

More... »

Shire, Foundation Fighting Blindness ink research agreement for rare pediatric eye disease

Monday, May 4, 2015 01:01 PM

Shire and the Foundation Fighting Blindness, a national nonprofit organization focused on the entire spectrum of retinal diseases, have formed a new agreement to further research for a novel treatment for autosomal dominant retinitis pigmentosa (adRP), a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There currently are no approved treatment options for adRP.

More... »

PPD recognized for excellence in clinical research in 2015 CRO Leadership Awards

Monday, May 4, 2015 12:42 PM

Pharmaceutical Product Development (PPD) has been recognized for excellence in clinical research by pharmaceutical and biotechnology company executives surveyed for Life Science Leader magazine’s 2015 CRO Leadership Awards.

More... »

Culture: A Growth Medium for Excellence

Monday, May 4, 2015 08:00 AM

Recently I learned about a seminar delivered by the customer service experts of the Ritz Carlton Hotel group.

More... »

FDA’s Woodcock proposes master protocols, infrastructure to increase clinical trial efficiency, reduce costs

Monday, May 4, 2015 08:00 AM

The FDA, which has successfully reduced the review times for new medications, wants to help biopharmaceutical companies lower the rising costs of clinical trials by streamlining some of its processes and working more closely with industry.

More... »

NIH awards $17.9 million for blinding diseases research

Friday, May 1, 2015 12:58 PM

The National Eye Institute (NEI) has awarded five projects funds to develop new technology to noninvasively image cells of the eye as part of its Audacious Goals Initiative. NEI has committed $3.8 million to the projects in 2015 and up to $17.9 million over the next five years, pending the availability of funds. NEI is part of the National Institutes of Health.

More... »

OneBeacon Technology launches protocol-based clinical trials product

Friday, May 1, 2015 12:56 PM

OneBeacon Technology Insurance, a member of Minnetonka, Minn.-based OneBeacon Insurance Group, has launched its new "life of the clinical trial" product for North America, which extends clinical trials coverage through its products-completed operations policy form for the duration of each protocol period.

More... »

PRC Clinical partners with Statistics & Data Corp.

Friday, May 1, 2015 12:54 PM

Statistics & Data Corp. (SDC), a Tempe, Ariz.-based specialized biostatistics and clinical data management CRO, and PRC Clinical, a clinical trial management CRO based in Silicon Valley, Calif., have formalized a partnership and signed a strategic alliance agreement.

More... »

`

CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs